BOTOX for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis.

Trial Profile

BOTOX for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Neurogenic bladder; Urinary incontinence
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 20 Jul 2018 Results published in the Neurology
    • 10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov .
    • 11 Apr 2014 Last checked against United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top